Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

57%

4 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 4

4(100.0%)

4Total

Phase 4(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06927934Completed

Postmarketing Multicenter Study of Intra-Articular DIART ONE / EASYGO ONE for Knee Osteoarthritis

Role: lead

NCT04152096Phase 4Completed

Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Burns

Role: lead

NCT05043142Completed

Epidemiological Study of the COVID-2019 in Participating Organizations.

Role: lead

NCT03764085Phase 4Completed

Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Sepsis.

Role: lead

NCT03771170Phase 4Completed

Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Peritonitis

Role: lead

NCT03824457Phase 4Completed

Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Pneumonia

Role: lead

NCT04150367Terminated

Efficacy and Safety of Intravenous Treatment of Tuberculosis

Role: lead

All 7 trials loaded